TheraGlio - developing theranostics for gliomas.

MagForce AG

MagForce AG together with its subsidiaries MT MedTech Engineering GmbH and MagForce USA, Inc. is a leading medical device company in the field of nanomedicine in oncology. Founded in 1997, the company has offices in Berlin (headquarters) and Munich (both Germany) as well as Nevada U.S.A. The group's proprietary NanoTherm® therapy enables the focal treatment of solid tumors through the intratumoral generation of heat via activation of instilled superparamagnetic nanoparticles in an alternating magnetic field. NanoTherm®, NanoPlan® and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. The company has NanoTherm® therapy centers at the Charité-Universitätsmedizin hospital in Berlin, and the universit hospitals Münster, Kiel, Cologne and Frankfurt. Additional therapy centers in Germany are planned for 2015.

Main tasks attributed to the organisation: MagForce will support R&D activities in WP4, for the development of multifunctional nanoparticles for multimodal visualization. MagForce will provide its CE-certified NanoTherm AS1 nanoparticles with its background IP and with its experience in the field of cancer thermal therapy.